Vistin Pharma ASA : Proposal for Extraordinary Dividend


09.10.17 14:35
Meldung
 
Vistin Pharma ASA : Proposal for Extraordinary Dividend

Oslo, Norway, 9 October 2017

Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced today that the Board of Vistin Pharma will propose an extraordinary dividend of NOK 7.00 per share.

On 2 October, the Company announced the successful completion of the sale of its opioids and tablet manufacturing business to TPI Enterprises Limited, which resulted in the receipt of a provisional cash consideration of NOK 159.5 million. The sale is expected to have a positive net cash effect of NOK 140 - 150 million, before any transaction costs. As a result of this sale, the Board will call for an extraordinary general meeting to approve a dividend of NOK 7.00 per share (NOK 119.4 million).

Following the sale, Vistin Pharma is a pure play metformin producer, with a strong position in the global metformin market. The global market for metformin is expected to grow by four to five percent per annum, and Vistin Pharma is attractively positioned to capture part of this growth. The Company's project to double the production capacity for metformin is progressing according to plan, and the project will be presented in further details in the third quarter financial report to be released on 27 October.

For further information, please contact:

Kjell-Erik Nordby

CEO

+47 91 36 42 80

kjell-erik.nordby@vistin.com

Gunnar Manum

CFO

+47 95 17 91 90

gunnar.manum@vistin.com 

 
 
 
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Vistin Pharma ASA via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

VISTIN PHARMA ASA NK 1

Aktuelle Diskussionen zum Thema:


Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

VISTIN PHARMA ASA NK 1
Weitere Meldungen
 
10.10 Aker Solutions ASA: Invitat.
10.10 XPO Logistics Expands Data.
10.10 Elanders AB: Elanders make.
10.10 Medtronic to Establish Innov.
10.10 Biocartis Group NV: Disclosu.
09.10 Ad hoc: WILEX AG gibt Ä.
09.10 CORRECTION: Össur hf: Q3.
09.10 Össur hf: Q3 2017 Results .
09.10 LVMH: 12% ORGANIC REV.
09.10 Arcadis reports transactions.
09.10 Ageas reports on the progr.
09.10 Ad hoc: technotrans-Gruppe .
09.10 Ad hoc: Francotyp-Postalia .
09.10 Eastman Updates Full-Year 2.
09.10 Vistin Pharma ASA : Propo.
09.10 Net Insight AB: Net Insight .
09.10 Cargotec's financial informat.
09.10 Ad hoc: Holmes Investment .
09.10 Ad hoc: Correction of a rele.
09.10 Ad hoc: SAF-HOLLAND S.A.
09.10 Stolt-Nielsen Limited Reports.
09.10 Ad hoc: DIC Asset AG pla.
09.10 SCOR estimates the cost o.
06.10 New large TITANĀ® order fo.
06.10 Ad hoc: Holmes Investment .
06.10 Ageas and Norges Bank: Tr.
06.10 Ad hoc: Klarstellung: Überna.
06.10 Klövern AB (publ): Klövern .
06.10 Karo Pharma AB completes.
06.10 Ad hoc: RWE Aktiengesells.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 38274 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Amazon: Neues Kaufsignal!
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
Fresenius Aktie ...
Volker Gelfarth, (15.07.18)
Experte: Volker Gelfarth,
Web killed the Video killed ...
wikifolio.com, (15.07.18)
Experte: wikifolio.com,
Tesla: Das ist extrem ...
Robert Sasse, (15.07.18)
Experte: Robert Sasse,
Erweiterte Wirecard-...
Jörg Schulte, JS-Research (15.07.18)
Experte: Jörg Schulte, JS-Research
Zwei neue Zerobonds der ...
Börse Stuttgart AG, (15.07.18)
Experte: Börse Stuttgart AG,
Hat sich der DAX ...
Jürgen Schwenk, Herausgeber Bullenbrief (15.07.18)
Experte: Jürgen Schwenk, Herausgeber Bullenbrief
Fonds: Anleger setzen auf ...
Redaktion boerse-frankf., Deutsche Börse AG (14.07.18)
Experte: Redaktion boerse-frankfurt.de, Deutsche Börse AG
Mehr als 50 % Verlust
Bernd Niquet, Autor (14.07.18)
Experte: Bernd Niquet, Autor
Dow Jones: Und wieder an ...
Admiral Markets, (14.07.18)
Experte: Admiral Markets,
Baader Bond Market ...
Klaus Stopp, Baader Bank AG (14.07.18)
Experte: Klaus Stopp, Baader Bank AG
DOW DAX neuer Anlauf ...
Thomas Heydrich, Systemstradings.de (13.07.18)
Experte: Thomas Heydrich, Systemstradings.de
Unternehmer und ...
Claus Vogt, (13.07.18)
Experte: Claus Vogt,
Niquet's World
Neues vom Portal
 
Die einfache Blackjack-Kartenzähltechnik, die ein Spieler beherrschen muss
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen